Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$1.92 USD

1.92
866,033

-0.03 (-1.54%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.92 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for EBS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Emergent Biosolutions Inc. [EBS]

Reports for Purchase

Showing records 201 - 220 ( 237 total )

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 201

10/25/2012

Company Report

Pages: 6

Q3:12 Preview Second Opinion - Adjusting Estimates from Previous Preview -

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 202

10/24/2012

Daily Note

Pages: 4

Q3:12 Earnings Preview - Seasonally Strong BioThrax Numbers Anticipated

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 203

09/10/2012

Industry Report

Pages: 44

September 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 204

08/03/2012

Company Report

Pages: 6

Light Q2 Revenues but Stronger Back-Half Anticipated

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 205

05/06/2012

Company Report

Pages: 6

Q1 Seasonally Light Quarter as Anticipated - Focus Shifts to the TB Vaccine and TRU-016 as BioThrax Revenues Roll In - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 206

03/08/2012

Company Report

Pages: 6

Q4:11 Update - Anticipate Lower Q1 Revenue to Increase Later In the Year - TRU-016 Data at ASH 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 207

03/02/2012

Industry Report

Pages: 5

LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 208

01/05/2012

Daily Note

Pages: 5

Q4:11 Earnings Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 209

12/28/2011

Company Report

Pages: 7

Regains Rights to TRU-016 and Initiates Phase II Trial In CLL; Data H1:13

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 210

12/09/2011

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 211

12/07/2011

Daily Note

Pages: 5

American Society of Hematology Annual Meeting (ASH) 2011 Company Abstract

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 212

11/03/2011

Company Report

Pages: 6

Q3- Uptick in BioThrax Revenues Expected Q4

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 213

10/04/2011

Industry Report

Pages: 24

Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 214

10/03/2011

Company Report

Pages: 6

5 Year, 44.75 Million Doses, $1.25 Billion BioThrax Contract Announced - Lowering PT to $31 from $37

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 215

09/01/2011

Industry Report

Pages: 22

Biotechnology/Biopharmaceuticals/BioDefense: September 2011 Potential Milestones & Key Events - Monthly Update.

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 75.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 216

08/04/2011

Company Report

Pages: 7

Q2 Results Exceed Expectations

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 217

08/03/2011

Company Report

Pages: 6

Q2:11 Earnings Preview - Strong BioThrax Numbers Anticipated

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 218

08/02/2011

Company Report

Pages: 6

Q2:11 Earnings Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 219

05/26/2011

Company Report

Pages: 5

Sole Source RFP for 44.75 Million Doses of BioThrax Over 5 Years, Final Award Announcement Expected H2:11 - Increasing Price Target to $37 from $32

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Emergent Biosolutions Inc.

Industry: Medical - Biomedical and Genetics

Record: 220

05/09/2011

Company Report

Pages: 5

Weakness Unwarranted, Quarter Was No Surprise. Strong Quarter Ahead, in our Opinion

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party